[多发性硬化症/神经omyelitis光学谱障碍治疗的当前趋势:国内管理和个性化治疗的考虑]
1Kyoto MS Center, Kyoto Min-Iren Chuo Hospital.
Rinsho shinkeigaku = Clinical neurology
|April 29, 2025
概括
管理多发性硬化症和神经炎光学谱系障碍需要考虑误诊并尽量减少感染风险. 未来的疗法可能将重点放在髓再生,神经保护和个性化免疫复原上.
科学领域:
- 神经免疫学 神经免疫学
- 神经学 神经学
- 临床医学 临床医学
背景情况:
- 多发性硬化症 (MS) 和神经髓炎光学谱障碍 (NMOSD) 中复发的风险是一个重要的临床挑战.
- 目前的管理策略需要仔细考虑在复发期间潜在的错误诊断.
研究的目的:
- 讨论MS和NMOSD管理的不断变化的格局.
- 强调在复发管理中考虑误诊的重要性.
- 探索未来的治疗方向和个性化治疗方法.
主要方法:
- 对MS和NMOSD管理当前临床实践的审查.
- 对新兴治疗策略的分析.
- 在神经免疫学疾病中讨论个性化医学原则.
主要成果:
- 将复发风险降低到接近零并不总是可以实现的,这强调了对错误诊断的警的必要性.
- 有效的管理需要尽量减少感染风险,避免过度治疗.
- 未来的治疗可能会针对髓修复,神经元保护和免疫系统重置.
结论:
- 个性化治疗和免疫复合疗法是MS和NMOSD未来有希望的方向.
- 避免过度剂量和根据个体患者需求量身定制治疗对于最佳结果至关重要.
相关概念视频
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...